admin – Page 5495 – Get News Story

Dilated Cardiomyopathy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun

Key Dilated Cardiomyopathy Companies in the market include – Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun GmbH, Pfizer, Constant Therapeutics LLC, Cumberland Pharmaceuticals, and others.

DelveInsight’s “Dilated Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Dilated Cardiomyopathy, offering comprehensive insights into the Dilated Cardiomyopathy revenue trends, prevalence, and treatment landscape. The report delves into key Dilated Cardiomyopathy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Dilated Cardiomyopathy therapies. Additionally, we cover the landscape of Dilated Cardiomyopathy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Dilated Cardiomyopathy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Dilated Cardiomyopathy space.

To Know in detail about the Dilated Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dilated Cardiomyopathy Market Forecast

Some of the key facts of the Dilated Cardiomyopathy Market Report:

The Dilated Cardiomyopathy market size was valued ~USD 463 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the US had the largest market size for dilated cardiomyopathy, totaling approximately USD 329.4 million, surpassing the market sizes of the EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
In 2023, among the EU4 and the UK, Germany held the largest market for dilated cardiomyopathy at approximately USD 25.6 million, followed by France with around USD 20.8 million, while Spain had the smallest market, totaling about USD 14.4 million.
In 2023, Japan’s total market size for dilated cardiomyopathy was approximately USD 34.2 million, with expectations of growth by 2034.
Key Dilated Cardiomyopathy Companies: Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun GmbH, Pfizer, Constant Therapeutics LLC, Cumberland Pharmaceuticals, and others
Key Dilated Cardiomyopathy Therapies: Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), Ixmyelocel-T, COR-1, ARRY-371797, talfirastide, Ifetroban, and others.
The Dilated Cardiomyopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dilated Cardiomyopathy pipeline products will significantly revolutionize the Dilated Cardiomyopathy market dynamics.
DelveInsight’s estimates indicate that the total number of prevalent cases of dilated cardiomyopathy in the 7MM reached approximately 3,045,174 in 2023, with around 1,070,511 of those being diagnosed cases.
DelveInsight’s analysis estimates that, in 2023, the US accounted for about 51.8% of the total diagnosed prevalent cases of dilated cardiomyopathy in the 7MM, with the EU4 and the UK making up approximately 37.6%, and Japan around 10.6%.
DelveInsight’s epidemiology model for dilated cardiomyopathy estimates that, among the EU4 and the UK, Germany had the largest diagnosed prevalent population with around 103,096 cases in 2023, followed by France with approximately 83,529 diagnosed cases.
In 2023, among the gender-specific diagnosed prevalent cases of dilated cardiomyopathy in the EU4 and the UK, males accounted for approximately 298,709 cases, while females made up around 103,829 cases.

Dilated Cardiomyopathy Overview

Dilated cardiomyopathy (DCM) is a condition where the heart’s chambers, particularly the left ventricle, become enlarged and weakened, reducing the heart’s ability to pump blood efficiently. This can lead to heart failure and other complications. DCM can be caused by genetic factors, infections, high blood pressure, or other underlying conditions. Symptoms may include fatigue, shortness of breath, and swelling in the legs. Treatment options focus on managing symptoms and may include medications, lifestyle changes, or devices to support heart function, and in severe cases, a heart transplant may be needed.

Get a Free sample for the Dilated Cardiomyopathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/dilated-cardiomyopathy-market-forecast

Dilated Cardiomyopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dilated Cardiomyopathy Epidemiology Segmentation:

The Dilated Cardiomyopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalent Cases of Dilated Cardiomyopathy in the 7MM
Total Diagnosed Prevalent Cases of Dilated Cardiomyopathy in the 7MM
Gender-specific Cases of Dilated Cardiomyopathy in the 7MM
Familial and Non-familial Cases of Dilated Cardiomyopathy in the 7MM

Download the report to understand which factors are driving Dilated Cardiomyopathy epidemiology trends @ Dilated Cardiomyopathy Epidemiology Forecast

Dilated Cardiomyopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dilated Cardiomyopathy market or expected to get launched during the study period. The analysis covers Dilated Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dilated Cardiomyopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dilated Cardiomyopathy Therapies and Key Companies

Danicamtiv (MYK-491): Bristol Myers Squibb
BC007: Berlin Cures
DYSCORBAN (ifetroban): Cumberland Pharmaceuticals
Ixmyelocel-T: Vericel Corporation
COR-1: Corimmun GmbH
ARRY-371797: Pfizer
talfirastide: Constant Therapeutics LLC
Ifetroban: Cumberland Pharmaceuticals

Discover more about therapies set to grab major Dilated Cardiomyopathy market share @ Dilated Cardiomyopathy Treatment Landscape

Dilated Cardiomyopathy Market Strengths

Increasing prevalence of drug or alcohol abuse and cardiac muscle infections, they are more likely to develop dilated cardiomyopathy in the 7MM and are anticipated to fuel the market growth.
Recent advances in device therapies such as ICD, CRT, and surgical interventions have shown significant reductions in mortality and hospitalization rates among dilated cardiomyopathy patients.

Dilated Cardiomyopathy Market Opportunities

The increasing prevalence and public awareness can provide an opportunity to enhance the genetic basis of dilated cardiomyopathy, genetic screening for at-risk individuals, and its management.
Opportunities exist for pharmaceutical players to develop dilated cardiomyopathy therapies with improved efficacy, duration of action, and safety profiles, as well as to identify biomarkers.

Scope of the Dilated Cardiomyopathy Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Dilated Cardiomyopathy Companies: Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun GmbH, Pfizer, Constant Therapeutics LLC, Cumberland Pharmaceuticals, and others
Key Dilated Cardiomyopathy Therapies: Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), Ixmyelocel-T, COR-1, ARRY-371797, talfirastide, Ifetroban, and others
Dilated Cardiomyopathy Therapeutic Assessment: Dilated Cardiomyopathy current marketed and Dilated Cardiomyopathy emerging therapies
Dilated Cardiomyopathy Market Dynamics: Dilated Cardiomyopathy market drivers and Dilated Cardiomyopathy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Dilated Cardiomyopathy Unmet Needs, KOL’s views, Analyst’s views, Dilated Cardiomyopathy Market Access and Reimbursement

To know more about Dilated Cardiomyopathy companies working in the treatment market, visit @ Dilated Cardiomyopathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Dilated Cardiomyopathy Market Report Introduction

2. Executive Summary for Dilated Cardiomyopathy

3. SWOT analysis of Dilated Cardiomyopathy

4. Dilated Cardiomyopathy Patient Share (%) Overview at a Glance

5. Dilated Cardiomyopathy Market Overview at a Glance

6. Dilated Cardiomyopathy Disease Background and Overview

7. Dilated Cardiomyopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Dilated Cardiomyopathy

9. Dilated Cardiomyopathy Current Treatment and Medical Practices

10. Dilated Cardiomyopathy Unmet Needs

11. Dilated Cardiomyopathy Emerging Therapies

12. Dilated Cardiomyopathy Market Outlook

13. Country-Wise Dilated Cardiomyopathy Market Analysis (2020–2034)

14. Dilated Cardiomyopathy Market Access and Reimbursement of Therapies

15. Dilated Cardiomyopathy Market Drivers

16. Dilated Cardiomyopathy Market Barriers

17. Dilated Cardiomyopathy Appendix

18. Dilated Cardiomyopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dilated Cardiomyopathy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun

Down Syndrome Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA

Key Down Syndrome Companies in the market include – Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA, AC Immune SA, AstraZeneca, and others.

DelveInsight’s “Down Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Down Syndrome, historical and forecasted epidemiology as well as the Down Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Down Syndrome, offering comprehensive insights into the Down Syndrome revenue trends, prevalence, and treatment landscape. The report delves into key Down Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Down Syndrome therapies. Additionally, we cover the landscape of Down Syndrome clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Down Syndrome treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Down Syndrome space.

To Know in detail about the Down Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Down Syndrome Market Forecast

Some of the key facts of the Down Syndrome Market Report:

The Down Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Key Down Syndrome Companies: Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA, AC Immune SA, AstraZeneca, and others
Key Down Syndrome Therapies: AEF0217, ACI-24.060, Donepezil HCl, E2020-Donepezil hydrochloride, RG1662, Florbetaben (BAY94-9172), ACI-24.060, Benralizumab, and others
The Down Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Down Syndrome pipeline products will significantly revolutionize the Down Syndrome market dynamics.
According to the DSAGSL organization (2022), around 400,000 Americans have been diagnosed with Down syndrome, and approximately 6,000 babies are born with the condition annually in the US.
According to the Minnesota Health Department (2023), Down syndrome occurs in 1 in 800 to 1,000 live births and is the most prevalent genetic cause of developmental delay in the US. The department also stated that there are three types of Down syndrome: trisomy 21 (nondisjunction), which accounts for 95% of cases; translocation, which accounts for about 4%; and mosaicism, which represents around 1%.
The Down Syndrome epidemiology based on gender analysed that males (54.5%) are affected slightly more than females (45.5%) with Down Syndrome
According to Hoshi et al., the overall prevalence of Down syndrome births in Japan was 5.82 per 10,000 live births.

Down Syndrome Overview

Down syndrome is a genetic disorder caused by the presence of an extra copy of chromosome 21, also known as trisomy 21. This condition leads to developmental delays, intellectual disabilities, and characteristic physical features such as a flattened face, almond-shaped eyes, and a short neck. People with Down syndrome may also experience health issues like heart defects, hearing problems, and a higher risk of certain medical conditions. While there is no cure, early intervention, educational support, and medical care can help individuals with Down syndrome lead fulfilling lives.

Get a Free sample for the Down Syndrome Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/down-syndrome-market

Down Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Down Syndrome Epidemiology Segmentation:

The Down Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Diagnosed Prevalent Cases of Down Syndrome in the 7MM
Type-specific Cases of Down Syndrome in the 7MM
Gender-specific Cases of Down Syndrome in the 7MM
Age-specific Cases of Down Syndrome in the 7MM
Treated Cases of Down Syndrome in the 7MM

Download the report to understand which factors are driving Down Syndrome epidemiology trends @ Down Syndrome Epidemiology Forecast

Down Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Down Syndrome market or expected to get launched during the study period. The analysis covers Down Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Down Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Down Syndrome Therapies and Key Companies

AEF0217: Aelis Farma
ACI-24.060: AC Immune SA
Donepezil HCl: Eisai Inc.
E2020-Donepezil hydrochloride: Eisai Co., Ltd.
RG1662: Hoffmann-La Roche
Florbetaben (BAY94-9172): Life Molecular Imaging SA
ACI-24.060: AC Immune SA
Benralizumab: AstraZeneca

Discover more about therapies set to grab major Down Syndrome market share @ Down Syndrome Treatment Landscape

Down Syndrome Market Drivers

Families, advocacy groups, and healthcare organizations offer strong support networks for individuals with Down syndrome, promoting awareness, research, and inclusive policies.
Advances in medical care and technology have improved the early detection of Down syndrome during pregnancy, allowing for better medical management and support.

Down Syndrome Market Barriers

Lack of approved medication for treating Down syndrome, provide pharma companies to bring novel therapies with first mover advantage.
Technology advancements, such as assistive devices, communication aids, and accessible applications, offer opportunities to enhance communication and daily living skills for individuals with Down syndrome.

Scope of the Down Syndrome Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Down Syndrome Companies: Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA, AC Immune SA, AstraZeneca, and others
Key Down Syndrome Therapies: AEF0217, ACI-24.060, Donepezil HCl, E2020-Donepezil hydrochloride, RG1662, Florbetaben (BAY94-9172), ACI-24.060, Benralizumab, and others
Down Syndrome Therapeutic Assessment: Down Syndrome current marketed and Down Syndrome emerging therapies
Down Syndrome Market Dynamics: Down Syndrome market drivers and Down Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Down Syndrome Unmet Needs, KOL’s views, Analyst’s views, Down Syndrome Market Access and Reimbursement

To know more about Down Syndrome companies working in the treatment market, visit @ Down Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Down Syndrome Market Report Introduction

2. Executive Summary for Down Syndrome

3. SWOT analysis of Down Syndrome

4. Down Syndrome Patient Share (%) Overview at a Glance

5. Down Syndrome Market Overview at a Glance

6. Down Syndrome Disease Background and Overview

7. Down Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Down Syndrome

9. Down Syndrome Current Treatment and Medical Practices

10. Down Syndrome Unmet Needs

11. Down Syndrome Emerging Therapies

12. Down Syndrome Market Outlook

13. Country-Wise Down Syndrome Market Analysis (2019–2032)

14. Down Syndrome Market Access and Reimbursement of Therapies

15. Down Syndrome Market Drivers

16. Down Syndrome Market Barriers

17. Down Syndrome Appendix

18. Down Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Down Syndrome Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA

Diabetic Macular Edema Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharma, RemeGen

Key Diabetic Macular Edema Companies in the market include – Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharmaceuticals, RemeGen Co., Ltd., Alimera Sciences, Curacle Co., Ltd., Faricimab: Genentech, Inc., and others.

DelveInsight’s “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diabetic Macular Edema, historical and forecasted epidemiology as well as the Diabetic Macular Edema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Diabetic Macular Edema, offering comprehensive insights into the Diabetic Macular Edema revenue trends, prevalence, and treatment landscape. The report delves into key Diabetic Macular Edema statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Diabetic Macular Edema therapies. Additionally, we cover the landscape of Diabetic Macular Edema clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Diabetic Macular Edema treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Diabetic Macular Edema space.

To Know in detail about the Diabetic Macular Edema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Macular Edema Market Forecast

Some of the key facts of the Diabetic Macular Edema Market Report:

The Diabetic Macular Edema market size was valued ~USD 2.9 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2022, the market size for diabetic macular edema (DME) across the United States, EU4 (Germany, Spain, Italy, France), the UK, and Japan was approximately USD 2,911 million.
The market size is projected to grow during the forecast period (2023–2034) due to the introduction of upcoming therapies. In 2022, the United States held the largest market share, with an estimated size of approximately USD 1,745 million.
Key Diabetic Macular Edema Companies: Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharmaceuticals, RemeGen Co., Ltd., Alimera Sciences, Curacle Co., Ltd., Faricimab: Genentech, Inc., and others
Key Diabetic Macular Edema Therapies: OCS-01, THR-149, Ranibizumab, EXN407, IBE-814, EYP-1901, RC-28E, Aflibercept, Conbercept, CU06-1004, and others
The Diabetic Macular Edema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Macular Edema pipeline products will significantly revolutionize the Diabetic Macular Edema market dynamics.
DelveInsight’s analysis revealed that the total prevalent cases of diabetic macular edema (DME) in the 7MM reached 1,073,892 in 2022, with expectations of a significant compound annual growth rate (CAGR) throughout the study period.
The United States had the highest number of diagnosed prevalent cases of diabetic macular edema (DME), estimated at approximately 483,251 in 2022, and is expected to see a significant increase at a compound annual growth rate (CAGR).
The diagnosed prevalent cases of diabetic macular edema (DME) were classified into three age groups: 18-44 years, 45-64 years, and 75 years and older. In 2022, the age group of 45-64 years had the highest number of cases, totaling 209,740 in the US.

Diabetic Macular Edema Overview

Diabetic macular edema (DME) is a complication of diabetes that occurs when high blood sugar levels damage the blood vessels in the retina, leading to fluid leakage and swelling in the macula, the central part of the retina responsible for sharp vision. This condition can cause blurred or distorted vision and may result in significant vision loss if not treated. DME is often associated with diabetic retinopathy, and management may include controlling blood sugar levels, laser therapy, or injections of medications to reduce swelling and improve vision.

Get a Free sample for the Diabetic Macular Edema Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market

Diabetic Macular Edema Epidemiology

Diabetic Macular Edema Epidemiology Segmentation:

The Diabetic Macular Edema market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalent Cases of DME in the 7MM
Total Diagnosed Prevalent Cases of DME in the 7MM
Gender-specific Diagnosed Prevalent Cases of DME in the 7MM
Age-Specific Diagnosed Prevalent Cases of DME in the 7MM
Subgroup-specific Diagnosed Prevalent Cases of DME in the 7MM
Treated cases of DME in the 7MM

Download the report to understand which factors are driving Diabetic Macular Edema epidemiology trends @ Diabetic Macular Edema Epidemiology Forecast

Diabetic Macular Edema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Macular Edema market or expected to get launched during the study period. The analysis covers Diabetic Macular Edema market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Diabetic Macular Edema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Macular Edema Therapies and Key Companies

OCS-01: Oculis
THR-149: Oxurion
Ranibizumab: Novartis
EXN407: Exonate Limited
IBE-814: Ripple Therapeutics
EYP-1901: EyePoint Pharmaceuticals
RC-28E: RemeGen Co., Ltd.
Aflibercept: Alimera Sciences
Conbercept: RemeGen Co., Ltd.
CU06-1004: Curacle Co., Ltd.
Faricimab: Genentech, Inc.

Discover more about therapies set to grab major Diabetic Macular Edema market share @ Diabetic Macular Edema Treatment Landscape

Diabetic Macular Edema Market Strengths

Late-stage pipeline drugs such as Faricimab, Beovuand KSI-301 are some of the potential emerging therapies that have shown promising results and expected to improve the dosing interval

Diabetic Macular Edema Market Opportunities

Around in one-quarter or more of eyes with center involving DME do not achieve complete resolution of the edema with anti-VEGF therapy and currently there is no curative treatment options for this refractory pool.

Scope of the Diabetic Macular Edema Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Diabetic Macular Edema Companies: Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharmaceuticals, RemeGen Co., Ltd., Alimera Sciences, Curacle Co., Ltd., Faricimab: Genentech, Inc., and others
Key Diabetic Macular Edema Therapies: OCS-01, THR-149, Ranibizumab, EXN407, IBE-814, EYP-1901, RC-28E, Aflibercept, Conbercept, CU06-1004, and others
Diabetic Macular Edema Therapeutic Assessment: Diabetic Macular Edema current marketed and Diabetic Macular Edema emerging therapies
Diabetic Macular Edema Market Dynamics: Diabetic Macular Edema market drivers and Diabetic Macular Edema market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Diabetic Macular Edema Unmet Needs, KOL’s views, Analyst’s views, Diabetic Macular Edema Market Access and Reimbursement

To know more about Diabetic Macular Edema companies working in the treatment market, visit @ Diabetic Macular Edema Clinical Trials and Therapeutic Assessment

Table of Contents

1. Diabetic Macular Edema Market Report Introduction

2. Executive Summary for Diabetic Macular Edema

3. SWOT analysis of Diabetic Macular Edema

4. Diabetic Macular Edema Patient Share (%) Overview at a Glance

5. Diabetic Macular Edema Market Overview at a Glance

6. Diabetic Macular Edema Disease Background and Overview

7. Diabetic Macular Edema Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Macular Edema

9. Diabetic Macular Edema Current Treatment and Medical Practices

10. Diabetic Macular Edema Unmet Needs

11. Diabetic Macular Edema Emerging Therapies

12. Diabetic Macular Edema Market Outlook

13. Country-Wise Diabetic Macular Edema Market Analysis (2020–2034)

14. Diabetic Macular Edema Market Access and Reimbursement of Therapies

15. Diabetic Macular Edema Market Drivers

16. Diabetic Macular Edema Market Barriers

17. Diabetic Macular Edema Appendix

18. Diabetic Macular Edema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Macular Edema Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharma, RemeGen

Shopr Rewards Secures Premium Office Space in Downtown Orlando

“Towering over neighboring Lake Eola, OneEleven is a stunning mixed-use project comprised of a dynamic blend of commercial, residential, and retail space.”

New office space sets the foundation for future growth, strategically located in Orlando’s Central Business District

Orlando, Fla. – September 24, 2024 – Shopr Rewards (“Shopr” or the “company”), an innovative provider of instant cash back rewards in the travel industry and beyond, will be moving to a new downtown Orlando location, securing nearly 5,000 square feet of prime Class A office space at 111 N. Magnolia Avenue. The build-out of the office is already underway, with the team expected to move in this October.

“This new space provides us with an ideal base to better serve our clients, both locally and globally,” said Paul Mattimoe, president and CEO of Shopr. “As we continue to grow and expand, this space will allow us to strengthen our operations and better support the evolving needs of our partners worldwide while also establishing a strong presence in Orlando.”

Located on the 15th floor of the OneEleven building, the office offers panoramic views of Lake Eola and downtown Orlando and has received numerous annual accolades, including previously being named Orlando’s “Coolest Office Space” by the Orlando Business Journal.

“Our move to this new downtown Orlando location reflects our commitment to growth and innovation,” said Sharon Mattimoe, COO of Shopr. “It gives us the flexibility to scale and provides the right environment for our team to continue delivering exceptional service and results to our global customer base, fostering collaboration and driving innovation across our operations.”

“The decision to secure this space in the heart of Orlando underscores our dedication to building strong relationships with partners and customers in one of the world’s top destinations,” said Alex Glover, vice president of marketing and strategic partnerships at Shopr. “This move is an exciting step toward expanding our brand and creating new opportunities for strategic growth in the loyalty rewards sector.”

The move comes as Shopr Rewards continues to expand its team and its offerings in the loyalty rewards space, offering users cashback redeemable for travel and other experiences.

About Shopr Rewards, LLC

Shopr Rewards (https://www.shoprapp.com) is a cutting-edge mobile shopping app that revolutionizes customer engagement and loyalty by offering instant cash back rewards at over 325 major retail, restaurant, and recreation brands. Designed to integrate seamlessly with existing loyalty programs, Shopr empowers businesses to drive transactions and future revenue by allowing customers to earn and redeem cash back directly through the app. With features like targeted push notifications, advanced purchase behavior analytics, and customizable promotional offers, Shopr not only enhances the customer experience but also provides valuable insights to help businesses better engage with their audience. Through its innovative approach, Shopr helps users save hundreds, if not thousands, of dollars annually, while enabling businesses to grow their revenue and foster long-term customer relationships.

Media Contact
Company Name: Shopr Rewards
Contact Person: Media Relations
Email: Send Email
Phone: 3213597099
Address:111 N. Magnolia Avenue Suite 1575
City: Orlando
State: FL
Country: United States
Website: www.shoprapp.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Shopr Rewards Secures Premium Office Space in Downtown Orlando

Visionary Entrepreneur, Bill McGowan Shares Over 50 Years of Business Expertise in Be Your Own Boss, A Practical Guide to Starting or Buying a Business

Even at the best of times, starting a business is no easy task. In Be Your Own Boss, award-winning entrepreneur Bill McGowan breaks down the process into simple, manageable steps, showing how anyone can start their own business, and if it’s the right next step to take.

Bill McGowan is an award-winning author, motivational speaker, business consultant and the founder of Fastway Group, an internationally franchised courier business. Established in 1983, Fastway became a household name in the franchising and transport sectors of Australia and New Zealand, turning over half a billion dollars per year and employing over 3,000 people around the world.

A prolific entrepreneur, Bill has been self-employed since the 1970’s, starting and selling many businesses over the past 50 years. With prominence in the franchise industry, he served as chairman of the Franchise Council of Australia, World Franchise Council and Australian Franchising Hall of Fame Committee, along with being Inducted to the Franchise Hall of Fame of Australia in 2003, receiving the Exemplary Role Model of the International Franchise Community Award and a life member of the NZ Franchise association.

A highly sought-after speaker, Bill has shared his wisdom and insights at conferences and corporate events in over 30 countries around the world. His speeches focus on topics including franchising, sales and marketing, logistics, business planning, goal setting, team building and more. Today, Bill leads the WA McGowan Advisory team, solving business challenges that improve growth and efficiency.

This one-on-one interview shares Bill McGowan’s background and experience writing Be Your Own Boss.

Tell us about Be Your Own Boss.

Be Your Own Boss is a practical guide to starting your own business, designed to help people understand whether being their own boss is really for them.

The book covers my personal experience of researching business opportunities, overcoming obstacles, and teaching others how to operate their own businesses. It contains actionable checklists, questionnaires, and advice, so readers can learn how to break into business, set and meet effective goals, plan their business operations, obtain financing, market their products and services, and more. In addition, the last stretch of the book is devoted to my specialty, franchising.

Every person who aspires to be their own boss will benefit greatly from the business wisdom that I share in the book – wisdom that is practical, accessible, and has been forged from my own hands-on-experience in identifying a business opportunity, developing it, and growing it into a multi-million-dollar venture.

What inspired you to write Be Your Own Boss?

I have been self-employed in various businesses since the early 1970s.

At the age of 13, I started a lawn mowing business, employing up to 12 boys and servicing 100 clients. When I first entered the franchise world in 1983, I was shocked at how many potential franchisees had no idea about running their own business.

Even at the best of times, starting a new business is a delicate, complex endeavor.

So, when I semi-retired, I decided to put all of the knowledge I had learned over the past 50 years of starting and selling businesses into a book.

In Be Your Own Boss, I describe a step-by-step process I developed to help potential franchisees work out whether self-employment of any form is really for them. My goal was to make the process as manageable as possible for the intending entrepreneur.

What is one message you would like readers to remember?

If you have dreams of owning your own business and being your own boss, this book is for you.

If you are currently an employee, at a crossroads of whether or not starting a business is the right next step, this book can help.

If you are looking at achieving financial freedom, now and into retirement, this book can show you the way.

If you want to learn how to maximize your strengths and work on your weaknesses, you are in the right place.

With illustrations, checklists, guiding questions and working plans, my aim is for you to use this book to organize your thoughts and ideas and decide if owning your own business is right for you. If it is, you can use this book to help build the business and life of your dreams!

Purchasing the Book

Be Your Own Boss has received positive reviews from well-known experts, authors, and reviewers around the world. Book Excellence writes, “Be Your Own Boss offers a wealth of valuable information on building a business and getting into franchising; it is clear and user-friendly, offering important foundations for both business and life.” In addition, David Tran, Operations Manager of the National Facilities Management in Sydney, Australia, writes, “This book provides practical advice, real-world examples, and an entrepreneurial mindset that is essential for success in today’s business world.”

Be Your Own Boss is available for sale on Amazon and other online bookstores. Readers are encouraged to purchase their copy today: https://www.wamcgowan.com/beyourownboss

To connect with Bill, purchase a copy of the book and learn more about his services, visit: https://www.wamcgowan.com/. You can also find him on LinkedIn.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Visionary Entrepreneur, Bill McGowan Shares Over 50 Years of Business Expertise in Be Your Own Boss, A Practical Guide to Starting or Buying a Business

Diabetic Kidney Disease Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth Corp.

Key Diabetic Kidney Disease Companies in the market include – Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth Corporation, Eli Lilly and Company, Korea Otsuka Pharmaceutical, BioStratum, Fresenius Kabi, and others.

DelveInsight’s “Diabetic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diabetic Kidney Disease, historical and forecasted epidemiology as well as the Diabetic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Diabetic Kidney Disease, offering comprehensive insights into the Diabetic Kidney Disease revenue trends, prevalence, and treatment landscape. The report delves into key Diabetic Kidney Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Diabetic Kidney Disease therapies. Additionally, we cover the landscape of Diabetic Kidney Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Diabetic Kidney Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Diabetic Kidney Disease space.

To Know in detail about the Diabetic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Kidney Disease Market Forecast

Some of the key facts of the Diabetic Kidney Disease Market Report:

The Diabetic Kidney Disease market size was vlaued ~USD 7,200 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
Key Diabetic Kidney Disease Companies: Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth Corporation, Eli Lilly and Company, Korea Otsuka Pharmaceutical, BioStratum, Fresenius Kabi, and others
Key Diabetic Kidney Disease Therapies: CU01-1001, BI 685509, BAY94-8862, PF-00489791, Canagliflozin, PH3, LY3016859, Probucol, Pyridorin, Ketosteril®, and others
The Diabetic Kidney Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Kidney Disease pipeline products will significantly revolutionize the Diabetic Kidney Disease market dynamics.
According to DelveInsight’s estimates, the total prevalent cases of diabetes in the 7MM were approximately 82,858,700 in 2023, with a projected increase over the study period.
In 2023, the United States had the highest number of diagnosed prevalent cases of diabetic kidney disease (DKD), with roughly 5,141,000 cases.
DKD is predominantly observed in individuals aged 60 and above, accounting for 70% of cases. In the US, age-specific cases of DKD in 2023 were approximately 1,542,000 in the 18–59 age group and around 3,600,000 in the 60+ age group.

Diabetic Kidney Disease Overview

Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a common complication of diabetes that affects the kidneys’ ability to filter waste from the blood. High blood sugar levels damage the tiny blood vessels in the kidneys, leading to impaired kidney function and potentially kidney failure over time. Symptoms may include swelling, high blood pressure, and protein in the urine. DKD is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Managing diabetes, controlling blood pressure, and early treatment can help slow the progression of the disease.

Get a Free sample for the Diabetic Kidney Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-market

Diabetic Kidney Disease Epidemiology

Diabetic Kidney Disease Epidemiology Segmentation:

The Diabetic Kidney Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalent Cases of Diabetes in the 7MM
Total Prevalent Cases of DKD in the 7MM
Diagnosed Prevalent Cases of DKD in the 7MM
Age-specific Cases of DKD in the 7MM
Stage-specific Cases of DKD in the 7MM

Download the report to understand which factors are driving Diabetic Kidney Disease epidemiology trends @ Diabetic Kidney Disease Epidemiology Forecast

Diabetic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Kidney Disease market or expected to get launched during the study period. The analysis covers Diabetic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Diabetic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Kidney Disease Therapies and Key Companies

CU01-1001: Curacle Co., Ltd.
BI 685509: Boehringer Ingelheim
BAY94-8862: Bayer
PF-00489791: Pfizer
Canagliflozin: Mitsubishi Tanabe Pharma
PH3: PhytoHealth Corporation
LY3016859: Eli Lilly and Company
Probucol: Korea Otsuka Pharmaceutical
Pyridorin: BioStratum
Ketosteril®: Fresenius Kabi

Discover more about therapies set to grab major Diabetic Kidney Disease market share @ Diabetic Kidney Disease Treatment Landscape

Diabetic Kidney Disease Market Strengths

Many major companies are investing in different mechanisms of action for the treatment of DKD, peripherally-acting CB1r blockers, IL-33-neutralizing mAb, ETA receptor antagonists, aldosterone synthase inhibitor (ASi), mineralocorticoid receptor (MR) blockers, and others which will boost the DKD market in the future.
A unique trial testing of BI 690517, a selective aldosterone synthase inhibitor along with SGLT2 inhibition, showed positive efficacy, offering the potential for additive kidney benefits while possibly mitigating hyperkalemia risk.

Diabetic Kidney Disease Market Opportunities

Personalized medicine, considering the genetic and mechanistic variability, will improve renal and cardiovascular protection in diabetic patients with CKD.
The concept of “metabolic memory” in diabetic patients, where prior exposure to elevated blood glucose levels results in enduring detrimental effects despite glycemic control, opens a window of opportunity to develop genetic interventions such as CRISPR–Cas editing to potentially erase this memory and offer novel therapeutic avenues for diabetic kidney disease.

Scope of the Diabetic Kidney Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Diabetic Kidney Disease Companies: Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth Corporation, Eli Lilly and Company, Korea Otsuka Pharmaceutical, BioStratum, Fresenius Kabi, and others
Key Diabetic Kidney Disease Therapies: CU01-1001, BI 685509, BAY94-8862, PF-00489791, Canagliflozin, PH3, LY3016859, Probucol, Pyridorin, Ketosteril®, and others
Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies
Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Diabetic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Diabetic Kidney Disease Market Access and Reimbursement

To know more about Diabetic Kidney Disease companies working in the treatment market, visit @ Diabetic Kidney Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Diabetic Kidney Disease Market Report Introduction

2. Executive Summary for Diabetic Kidney Disease

3. SWOT analysis of Diabetic Kidney Disease

4. Diabetic Kidney Disease Patient Share (%) Overview at a Glance

5. Diabetic Kidney Disease Market Overview at a Glance

6. Diabetic Kidney Disease Disease Background and Overview

7. Diabetic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Kidney Disease

9. Diabetic Kidney Disease Current Treatment and Medical Practices

10. Diabetic Kidney Disease Unmet Needs

11. Diabetic Kidney Disease Emerging Therapies

12. Diabetic Kidney Disease Market Outlook

13. Country-Wise Diabetic Kidney Disease Market Analysis (2020–2034)

14. Diabetic Kidney Disease Market Access and Reimbursement of Therapies

15. Diabetic Kidney Disease Market Drivers

16. Diabetic Kidney Disease Market Barriers

17. Diabetic Kidney Disease Appendix

18. Diabetic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Kidney Disease Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth Corp.

Hypeal.com and TA-DAAN Introduce a Cutting-Edge VIP Membership Program on Shopify’s App Store.

The Prime Experience for Shopify Brands

Amsterdam – September 24th, 2024 – Hypeal.com is excited to announce the launch of TA-DAAN’s VIP Memberships, a groundbreaking loyalty program set to transform customer engagement and boost sales for Shopify brands. This innovative program, now available on the Shopify App Store, offers a range of exclusive benefits tailored to enhance the shopping experience and foster brand loyalty.

Introducing TA-DAAN’s VIP Membership: For just €29 per year, TA-DAAN’s VIP Membership provides customers with unparalleled value and access to a host of exclusive benefits:

15% Instant Discount: Enjoy an immediate 15% off your cart when you add the TA-DAAN VIP Membership to your order.

10% OFF for One Year: Receive a 10% discount on all future orders for an entire year (up to a maximum of 20% off).

Free Shipping: Benefit from free shipping on orders over €150.

Early Access: Get early access to limited edition products.

Exclusive Events: Attend members-only events and experiences.

TA-DAAN’s VIP Membership is a testament to Hypeal’s commitment to reshaping the e-commerce landscape by providing brands with the tools they need to offer compelling, value-driven loyalty programs. Learn more about the membership here.

About TA-DAAN:

TA-DAAN is an innovative startup founded in 2020 by Roberta Ligossi, Sara Pianori, Costanza Tomba, and Valeria Zanirato, with the aim of promoting, supporting, and actively empower the new generation of artisans and therefore contemporary craftsmanship, through a content e-commerce, and the creation of editorial and digital content on various social platforms, as well as offline and online experiential events. Among TA-DAAN’s cornerstones: creativity, uniqueness, and awareness.

Hypeal:

Empowering E-commerce Brands Hypeal.com is a B2B SaaS tech startup empowering e-commerce brands to launch their VIP membership programs, unlocking recurring revenue for the brands and exclusive experiences for members through Hypeal™ gating technology, using blockchain. Since August 2023, Hypeal has raised $200,000 from ABN AMRO and Techstars. The team, led by Forbes 30 Under 30 honoree in Retail and E-commerce 2024, has a proven track record of success in the e-commerce industry.

Join the Revolution:

Experience the future of e-commerce loyalty programs with Hypeal and TA-DAAN’s VIP Memberships. Discover how these programs can boost your Average Order Value (AOV), increase purchase frequency, and generate new revenue streams.For more information and to get started, visit Hypeal on the Shopify App Store.

About Hypeal:

Hypeal.com is at the forefront of e-commerce innovation, offering unique loyalty solutions that drive customer engagement and brand loyalty. Our mission is to replace third-party ad dependency with first-party data sharing, rewarding shoppers for their brand loyalty and creating a seamless shopping experience.

Media Contact
Company Name: Hypeal.com
Contact Person: Ta-Daan Marta Delpiano
Email: Send Email
Country: Netherlands
Website: https://hypeal.com/

Eightco Holdings Inc. Is Ripe For Appreciation After Scoring Q3 Milestone (NASDAQ: OCTO)

Investing really isn’t that difficult. Do some research, find untapped value in a company disrupting sector landscapes, and capitalize on that open window of opportunity. Completing the first two measures leads to a company like Eightco Holdings Inc. (NASDAQ: OCTO). Then, by taking that third action, especially while OCTO is still relatively under-the-radar of many, investors may find themselves positioned to maximize ROI from a ground-floor entry point. But know this: while the window of opportunity is open, don’t expect the bargain price to last.

In fact, the near-term path of least resistance for OCTO shares looks paved higher after the company reached a key Q3 milestone by regaining NASDAQ listing compliance. This accomplishment is more than just a regulatory win; it’s a powerful affirmation of OCTO’s financial resilience and strategic vision. By the way, the company did more than meet the minimums required to regain compliance; they crushed them by exceeding stockholders’ equity requirement by a substantial margin, reporting $13.4 million in equity, well above the $2.5 million threshold. Additionally, the closing bid price of its common stock remained above $1.00 for 20 consecutive trading days, doubling the minimum.

In addition to restoring investor confidence, the listing strengthens the foundation for OCTO to pursue its aggressive growth strategy, unhindered by past financial constraints. In fact, a much stronger and NASDAQ-listed OCTO now has untethered access to capital markets, institutional interest and support, and open doors to top-tier resources that can expedite steepening its revenue curve, drop more net income to its bottom line, and enhance shareholder value. Its NASDAQ listing wasn’t the only milestone reached this year.

A milestone-rich 2024

So far in 2024, OCTO has significantly improved its balance sheet, eliminated $5.4 million in convertible notes, and canceled over $23 million in liabilities. These actions not only pave a consistent path toward net income but also underscore OCTO’s commitment to financial discipline. The company’s work is already paying off, with OCTO reporting a net income of $4.4 million in Q2, a significant improvement over the ($8.9) million net loss in the prior year’s same quarter. This turnaround was not a coincidence of good fortune but a result of better operating performance, elimination of warrant losses, and margin increases. Regarding the latter, OCTO’s gross profit margin more than doubled, surging to 25.3%, up from 12.3% in the previous year. The company also slashed SG&A expenses by 26.6%. These financial improvements are not just numbers—they are the tangible results of a company reshaping its future that points to a new era of profitability.

With that in mind, growth stock investors may want to seize this opportunity sooner rather than later. Plenty supports doing so, including a book value calculation supporting an OCTO stock price of over $7.00. However, an increase to book value of over 228% from its current $2.13 share price may only be a rest stop and not a final destination, especially when factoring in strategic decisions and actions that have accelerated OCTO’s mission to deliver a great Q4 and even better 2025. Turning an ambitious mission into dollars is more than likely, it’s probable, especially with its main wholly owned subsidiary, Forever 8 Fund LLC is emerging as a player in the rapidly expanding e-commerce and refurbished electronics markets.

A valuable and revenue-generating subsidiary

Forever 8 provides an innovative inventory financing solution for small and mid-sized e-commerce businesses. Its model is particularly timely given the current e-commerce climate, where managing cash flow and maintaining adequate inventory levels often challenge sellers. Forever 8 addresses this problem by purchasing inventory on its client’s behalf. This allows them to allocate capital toward marketing, customer acquisition, and expanding product lines rather than tying it up in inventory. The innovative solution quickly alleviates the cash flow burden that often stifles brand growth, making it easier for sellers to scale their operations.

What makes Forever 8’s model especially compelling, and in demand, is its proprietary, data-driven tool that accurately assesses inventory risk. By leveraging historical sales data, demand trends, and other relevant factors, Forever 8 can make informed decisions about which products to stock and in what quantities. This predictive capability ensures efficient capital deployment and minimizes risk, creating value for both Forever 8 and its clients. The platform’s integration of inventory planning, purchasing, and payouts further simplifies the complex process of inventory management, enabling e-commerce sellers to scale with confidence and reduce their exposure to supply chain uncertainties.

Forever 8’s strategic venture into the refurbished Apple (NASDAQ: AAPL) products market further differentiates Forever 8 from other players in the e-commerce space. With consumer demand for cost-effective, high-quality electronics on the rise, particularly for refurbished Apple products like iPhones, iPads, and Apple Watches, this interest presents a significant growth opportunity. The rising popularity of refurbished electronics is driven by affordability and a shift toward eco-conscious consumerism, which values sustainable alternatives. By facilitating the resale of Apple products through major platforms like Amazon (NASDAQ: AMZN) and Shopify (NASDAQ: SHOP), Forever 8 taps into this growing market segment while aligning with broader sustainability trends.

Moreover, this expansion diversifies the company’s revenue streams and positions Forever 8 to capitalize on the burgeoning circular economy. By the way, Forever 8 is no newbie to the markets. As of July 2024, it crossed $100 million of Iphone sales. In other words, OCTO isn’t hoping to penetrate markets and exploit a major market opportunity- they already are.

A value proposition exposed

Expect them to continue seizing its opportunities. Based on its updates, Eightco remains focused on building on recent successes, prioritizing growing revenues. Now that OCTO has regained compliance for NASDAQ, that could happen faster than many may expect, especially as new doors open to assist in securing additional growth capital to energize its core business operations.

Noting OCTO’s impressive gross margins and demand in the refurbished electronics market surging, utilizing fresh capital could lead to a beat of optimistic forecasts. In other words, one of the next headlines in the queue could give investors a double dose of what drives share prices higher- top and bottom line growth. If so, with only about 1.78 million shares outstanding, it’s a fair assumption that the OCTO share price may react favorably. Considering the laws of supply and demand in market situations, perhaps exponentially so.

Disclaimers: This is sponsored content. Hawk Point Media Group, Llc. (HPM) has been compensated by Interactive Offers to produce and distribute digital content for Eightco Holdings, Inc. It should be expressly understood that HPM is not operated by a licensed broker, a dealer, or a registered investment adviser. It should also be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. HPM reports/releases are commercial advertisements and are for general information purposes ONLY. The information made available by HPM is not intended to be, nor does it constitute, investment advice or recommendations. The contributors do NOT buy and sell securities covered before or after any particular article, report and/or publication. HPM holds ZERO shares and has never owned stock in Eightco Holdings, Inc. While HPM does not own or market shares, it is prudent to expect that those hiring HPM including that company’s owners, employees, and affiliates, may sell some or even all of the Eightco Holdings, Inc. shares that they own, if any, during and/or after this engagement period. Always do your own due diligence prior to investing in any publicly traded company. For a full disclaimer and disclosure statement, click HERE.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eightco Holdings Inc. Is Ripe For Appreciation After Scoring Q3 Milestone (NASDAQ: OCTO)

Deep Vein Thrombosis Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Bayer, LEO Pharma, Agen Biomedical, MinaPharm Pharma, GlaxoSmithKline, Pfizer

Key Deep Vein Thrombosis Companies in the market include – Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others.

DelveInsight’s “Deep Vein Thrombosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Deep Vein Thrombosis, historical and forecasted epidemiology as well as the Deep Vein Thrombosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Deep Vein Thrombosis, offering comprehensive insights into the Deep Vein Thrombosis revenue trends, prevalence, and treatment landscape. The report delves into key Deep Vein Thrombosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Deep Vein Thrombosis therapies. Additionally, we cover the landscape of Deep Vein Thrombosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Deep Vein Thrombosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Deep Vein Thrombosis space.

To Know in detail about the Deep Vein Thrombosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Deep Vein Thrombosis Market Forecast

Some of the key facts of the Deep Vein Thrombosis Market Report:

The Deep Vein Thrombosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Key Deep Vein Thrombosis Companies: Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others
Key Deep Vein Thrombosis Therapies: Rivaroxaban, innohep®, ThromboView, Apixaban, SanOrg34006, Tinzaparin, edoxaban tosylate, r-Hirudin, Fondaparinux sodium, PD 0348292, Dalteparin, and others
The Deep Vein Thrombosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Deep Vein Thrombosis pipeline products will significantly revolutionize the Deep Vein Thrombosis market dynamics.
The Centers for Disease Control and Prevention (CDC) (2023) reports that while the exact number of individuals affected by DVT or PE is uncertain, it is estimated that up to 900,000 people may be impacted annually in the United States.
According to Waheed et al. (2023), over 200,000 individuals in the United States develop venous thrombosis each year, with 50,000 cases complicated by pulmonary embolism. The annual incidence of DVT is 80 cases per 100,000 people, with a prevalence of lower limb DVT at 1 case per 1,000 population.
Waheed et al. (2023) noted that deep vein thrombosis is uncommon in children, and the risk significantly rises with age, with most cases occurring in individuals over 40.
The CDC (2023) states that about 33% of individuals with DVT or PE will experience a recurrence within 10 years.

Deep Vein Thrombosis Overview

Deep vein thrombosis (DVT) is a condition where a blood clot forms in a deep vein, typically in the legs. This can cause pain, swelling, and discomfort. DVT is dangerous because the clot can break loose and travel to the lungs, leading to a life-threatening condition called pulmonary embolism. Risk factors include prolonged immobility, surgery, certain medications, and medical conditions that affect blood clotting. Treatment usually involves blood thinners to prevent clot growth and reduce the risk of complications. Early detection and treatment are critical to managing DVT effectively.

Get a Free sample for the Deep Vein Thrombosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/deep-vein-thrombosis-market

Deep Vein Thrombosis Epidemiology

Deep Vein Thrombosis Epidemiology Segmentation:

The Deep Vein Thrombosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalent Cases of DVT in the 7MM
Diagnosed Prevalent Cases of DVT in the 7MM
Age-specific Cases of DVT in the 7MM
Total Treated Cases of DVT in the 7MM

Download the report to understand which factors are driving Deep Vein Thrombosis epidemiology trends @ Deep Vein Thrombosis Epidemiology Forecast

Deep Vein Thrombosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Deep Vein Thrombosis market or expected to get launched during the study period. The analysis covers Deep Vein Thrombosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Deep Vein Thrombosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Deep Vein Thrombosis Therapies and Key Companies

Rivaroxaban: Bayer
innohep®: LEO Pharma
ThromboView: Agen Biomedical
Apixaban: Bristol-Myers Squibb
SanOrg34006: Sanofi
Tinzaparin: Ottawa Hospital Research Institute
edoxaban tosylate: Daiichi Sankyo
r-Hirudin: MinaPharm Pharmaceuticals
Fondaparinux sodium: GlaxoSmithKline
PD 0348292: Pfizer
Dalteparin: Anthos Therapeutics, Inc.

Discover more about therapies set to grab major Deep Vein Thrombosis market share @ Deep Vein Thrombosis Treatment Landscape

Deep Vein Thrombosis Market Strengths

The use of off-label branded and generic prescription medications targeted at individual symptoms of DVT.
Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of DVT.

Deep Vein Thrombosis Market Opportunities

New therapeutic options are needed to address the unmet need for effective and curative therapies for DVT. This has created an opportunity for key players to develop novel therapies targeted towards this indication.

Scope of the Deep Vein Thrombosis Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Deep Vein Thrombosis Companies: Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others
Key Deep Vein Thrombosis Therapies: Rivaroxaban, innohep®, ThromboView, Apixaban, SanOrg34006, Tinzaparin, edoxaban tosylate, r-Hirudin, Fondaparinux sodium, PD 0348292, Dalteparin, and others
Deep Vein Thrombosis Therapeutic Assessment: Deep Vein Thrombosis current marketed and Deep Vein Thrombosis emerging therapies
Deep Vein Thrombosis Market Dynamics: Deep Vein Thrombosis market drivers and Deep Vein Thrombosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Deep Vein Thrombosis Unmet Needs, KOL’s views, Analyst’s views, Deep Vein Thrombosis Market Access and Reimbursement

To know more about Deep Vein Thrombosis companies working in the treatment market, visit @ Deep Vein Thrombosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Deep Vein Thrombosis Market Report Introduction

2. Executive Summary for Deep Vein Thrombosis

3. SWOT analysis of Deep Vein Thrombosis

4. Deep Vein Thrombosis Patient Share (%) Overview at a Glance

5. Deep Vein Thrombosis Market Overview at a Glance

6. Deep Vein Thrombosis Disease Background and Overview

7. Deep Vein Thrombosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Deep Vein Thrombosis

9. Deep Vein Thrombosis Current Treatment and Medical Practices

10. Deep Vein Thrombosis Unmet Needs

11. Deep Vein Thrombosis Emerging Therapies

12. Deep Vein Thrombosis Market Outlook

13. Country-Wise Deep Vein Thrombosis Market Analysis (2019–2032)

14. Deep Vein Thrombosis Market Access and Reimbursement of Therapies

15. Deep Vein Thrombosis Market Drivers

16. Deep Vein Thrombosis Market Barriers

17. Deep Vein Thrombosis Appendix

18. Deep Vein Thrombosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Deep Vein Thrombosis Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Bayer, LEO Pharma, Agen Biomedical, MinaPharm Pharma, GlaxoSmithKline, Pfizer

Alieus Hedge Fund Raises $1.5 Million in Just 15 Days

“Mr. Ashish Jain, Founder and CEO of Alieus Hedge Fund”

Alieus Hedge Fund Raises $1.5 Million in Just 15 Days Since Inception on 7th September 2024, Breaking All Records. Founder and CEO, Mr. Ashish Jain, Leads Groundbreaking Achievement.

London – 24 September, 2024 – Alieus Hedge Fund, India’s first hedge fund designed for the common man, has achieved a remarkable milestone by raising $1.5 million within just 15 days of its launch. This record-breaking success underscores the fund’s innovative approach and rapid acceptance in the market.

Under the leadership of Mr. Ashish Jain, Founder and CEO, Alieus Hedge Fund has quickly garnered attention for its mission to democratize hedge fund investing, making it accessible to a broader audience beyond traditional high-net-worth individuals. The fund’s unique model has clearly resonated with investors, leading to unprecedented growth in an incredibly short period.

Mr. Ashish Jain, Founder and CEO, shared his thoughts on the achievement:

“Raising $1.5 million in just 15 days is an extraordinary milestone that confirms the demand for more inclusive investment opportunities. At Alieus Hedge Fund, we are committed to breaking down financial barriers and providing everyday investors with access to strategies typically reserved for the elite. We are proud to have set a new record and look forward to continuing this momentum.”

Alieus Hedge Fund’s early success positions it as a game-changer in the financial industry, and the team is eager to build on this momentum by expanding its offerings and continuing to drive change in the hedge fund space.

Alieus Hedge Fund is the first hedge fund in India dedicated to making hedge fund investment opportunities available to the common man. By providing access to sophisticated financial strategies traditionally available only to high-net-worth individuals, the fund aims to democratize wealth creation.

For more information, please visit: www.alieusfund.com

Media Contact
Company Name: Alieus Hedge Fund
Contact Person: Ashish Jain
Email: Send Email
Country: United Kingdom
Website: www.alieusfund.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alieus Hedge Fund Raises $1.5 Million in Just 15 Days